Fennec Pharmaceuticals (FENC) 10-K 15 Mar 19 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 11, 2019	Jun. 30, 2018
Document and Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Registrant Name	FENNEC PHARMACEUTICALS INC.
Entity Central Index Key	0001211583
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 82,970,261
Trading Symbol	FENCF
Entity Common Stock, Shares Outstanding		19,895,830
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	true

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 22,781	$ 28,260
Prepaid expenses	168	128
Other current assets	1	13
Total assets	22,950	28,401
Current liabilities:
Accounts payable	1,032	855
Accrued liabilities	605	622
Derivative instruments (Note 5)	0	167
Total current liabilities	1,637	1,644
Total liabilities	1,637	1,644
Commitments and Contingencies (Note 9)
Shareholders' equity:
Common stock, no par value; unlimited shares authorized; 19,896 shares issued and outstanding (2017-18,411)	106,392	103,045
Additional paid-in capital	44,934	43,837
Accumulated deficit	(131,256)	(121,368)
Accumulated other comprehensive income	1,243	1,243
Total shareholders' equity	21,313	26,757
Total liabilities and shareholders' equity	$ 22,950	$ 28,401

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Dec. 31, 2018	Dec. 31, 2017
Common stock, no par value	$ 0	$ 0
Common stock, shares issued	19,896	18,411
Common stock, shares outstanding	19,896	18,411

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue	$ 0	$ 0
Operating expenses:
Research and development	5,008	1,936
General and administrative	5,401	5,015
Loss from operations	(10,409)	(6,951)
Other income/(expense):
Unrealized gain/(loss) on derivatives (Note 5)	167	(134)
Other income/(loss)	6	(8)
Net interest income	348	47
Total other income/(loss), net	521	(95)
Net loss	$ (9,888)	$ (7,046)
Loss per common share, basic and diluted	$ (0.52)	$ (0.47)
Weighted-average number of common shares outstanding basic and diluted (Note 3)	18,942	15,014

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating activities:
Net loss	$ (9,888)	$ (7,046)
Adjustments to reconcile net (loss) to net cash used in operating activities:
Unrealized (gain)/loss on derivatives	(167)	134
Stock-based compensation - consultants	272	741
Stock-based compensation - employees	1,825	1,517
Changes in operating assets and liabilities:
Prepaid expenses	(40)	(85)
Other assets	12	(10)
Accounts payable	177	611
Accrued liabilities	(17)	497
Net cash used in operating activities	(7,826)	(3,641)
Investing activity:
Net cash used in investing activity	0	0
Financing activities:
Issuance of shares, net of issuance costs	0	27,381
Short swing profit judgment offset with settlement expense	18	0
Issuance of shares, options exercise	210	563
Issuance of shares, warrants exercise	2,119	31
Net cash provided by financing activities	2,347	27,975
(Decrease)/increase in cash and cash equivalents	(5,479)	24,334
Cash and cash equivalents - Beginning of year	28,260	3,926
Cash and cash equivalents - End of year	$ 22,781	$ 28,260

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income
Balance at Dec. 31, 2016	$ 3,570	$ 74,515	$ 42,134	$ (114,322)	$ 1,243
Balance (in shares) at Dec. 31, 2016		13,643
Stock options issued | Consultants [Member]	741	$ 0	741	0	0
Stock options issued | Employees [Member]	1,517	0	1,517	0	0
Exercise of stock options	563	$ 1,107	(544)	0	0
Exercise of stock options (in shares)		359
Exercise of warrants	31	$ 42	(11)	0	0
Exercise of warrants (in shares)		21
Issuance of securities	27,381	$ 27,381	0	0	0
Issuance of securities (in shares)		4,388
Net loss	(7,046)	$ 0	0	(7,046)	0
Balance at Dec. 31, 2017	26,757	$ 103,045	43,837	(121,368)	1,243
Balance (in shares) at Dec. 31, 2017		18,411
Short swing profit judgment offset with settlement expense	18	$ 0	18	0	0
Stock options issued | Consultants [Member]	272	0	272	0	0
Stock options issued | Employees [Member]	1,825	0	1,825	0	0
Exercise of stock options	210	$ 436	(226)	0	0
Exercise of stock options (in shares)		122
Exercise of warrants	2,119	$ 2,911	(792)	0	0
Exercise of warrants (in shares)		1,363
Net loss	(9,888)	$ 0	0	(9,888)	0
Balance at Dec. 31, 2018	$ 21,313	$ 106,392	$ 44,934	$ (131,256)	$ 1,243
Balance (in shares) at Dec. 31, 2018		19,896

Nature of Business and Liquidit

Nature of Business and Liquidity	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature Of Business And Liquidity [Text Block]	1. Nature of Business and Liquidity Fennec Pharmaceuticals Inc. (“Fennec,” “the Company,” “we,” “us,” or “our”) was originally formed as a British Columbia corporation under the name Adherex Technologies Inc. and subsequently changed its name on September 3, 2014. Fennec, together with its wholly owned subsidiaries Oxiquant, Inc. (“Oxiquant”) and Fennec Pharmaceuticals, Inc., both Delaware corporations, and Cadherin Biomedical Inc. (“CBI”), a Canadian corporation and Fennec Pharmaceuticals (EU) Limited (“Fennec Limited”), collectively referred to herein as the “Company,” is a biopharmaceutical company with a product candidate under development for use in the treatment of cancer. With the exception of Fennec Pharmaceuticals, Inc., all subsidiaries are inactive. These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) that are applicable to a going concern which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. During the year ended December 31, 2018, the Company incurred a net loss from operations of $10,409 and still has not earned any revenue in its history. At December 31, 2018, it had an accumulated deficit of $131,256 and had experienced negative cash flows from operating activities in the amount of $7,826 for the year ended December 31, 2018. On February 1, 2019, Fennec entered into a Loan and Security Agreement with Bridge Bank, a division of Western Alliance Bank, an Arizona corporation, pursuant to which the Bank agreed to loan $12.5 million to the Company, to be made available upon New Drug Application NDA approval of PEDMARK by no later than September 30, 2020. The proceeds from the loan will be used for working capital purposes and to fund general business requirements in accordance with the terms of the Loan and Security Agreement. Interest under the Term Loans shall bear interest, on the outstanding daily balance thereof, at a floating per annum rate equal to the Effective Interest Rate (as defined in the Loan and Security Agreement) which is equal to the sum of the Prime Rate published in the Wall Street Journal (currently 5.50%) plus one percent (1.00%). The debt facility is to have interest-only monthly payments due for the first eighteen months from the funding date and then monthly principal and interest payments are due through the remainder of the term which has a maturity date of October 1, 2023. In connection with the facility, Fennec has agreed to grant Bridge Bank a warrant to purchase up to 39,130 common shares at an exercise price of $6.80 per common share, for a term of ten years from the date of issuance, subject to early termination under certain conditions. The Company believes the aforementioned raise, along with the current cash on hand, provides sufficient funding for the Company to carry-out its planned activities for the next twelve to eighteen months as it continues its strategic development of PEDMARK TM These financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies Basis of presentation The consolidated financial statements include the accounts of Fennec and of all its wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated upon consolidation. Use of estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include the valuation of derivative warrant liability and the valuation of stock-based compensation. Actual results could differ from those estimates. Cash and Cash Equivalents Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less. The Company places its cash and cash equivalents in investments held by highly rated financial institutions in accordance with its investment policy designed to protect the principal investment. At December 31, 2018, the Company had $22.8 million in cash and money market accounts (2017- $28.3 million). Money market investments typically have minimal risks. The Company has not experienced any loss or write-down of its money market investments. Financial instruments Financial instruments recognized on the balance sheets at December 31, 2018 and December 31, 2017 consist of cash and cash equivalents, accounts payable, accrued liabilities and derivative instruments, the carrying values of which, with the exception of the derivative instruments, approximate fair value due to their relatively short time to maturity. The Company does not hold or issue financial instruments for trading. The derivative liabilities are carried at fair value. The Company’s investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments, when made, are made in U.S. or Canadian bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper. The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. As the main purpose of the Company is research and development, the Company has chosen to avoid investments of a trading or speculative nature. Common shares and warrants The Company has warrants outstanding to purchase common shares that were denominated in both United States dollars (“USD”) and Canadian dollars (“CAD”), which resulted in the Company having warrants outstanding that were denominated outside of the Company’s U.S. dollar functional currency. The Company’s outstanding warrants denominated in Canadian dollars were not considered to be indexed to the Company’s own stock and should therefore be treated as derivative financial instruments and recorded at their fair value as a liability. During the year ended December 31, 2018, all warrants accounted for as derivatives were exercised. These exercises reduced the derivative liability to $0 as of December 31, 2018. $167,000 $134,000 during the year ended December 31, 2017 . Revenue recognition At this time, the Company does not have any revenue. Research and development costs and investment tax credits Research costs, including employee compensation, laboratory fees, lab supplies, and research and testing performed under contract by third parties, are expensed as incurred. Development costs, including drug substance costs, clinical study expenses and regulatory expenses are expensed as incurred. Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made, and their realization is reasonably assured. They are applied to reduce related capital costs and research and development expenses in the year recognized. Income taxes The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December 31, 2018, we maintained a full valuation allowance against our deferred tax assets. The provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740-10, Uncertainty in Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. Foreign currency translation The U.S. dollar is the functional currency for the Company’s consolidated operations. All gains and losses from currency translations are included in results of operations. Loss per share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the year. Diluted net earnings per share is computed using the same method, except the weighted average number of common shares outstanding includes convertible debentures, stock options and warrants, if dilutive, as determined using the if-converted method and treasury methods. Accordingly, options to purchase 2.5 million of our common shares at December 31, 2018, were not included in earnings per share. Such options would have an antidilutive effect. In 2017, options to purchase 2.3 million common shares and warrants to purchase 1.4 million of our common shares were excluded from the computation of earnings per share as their inclusion would have been antidilutive. Recent accounting pronouncements In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 removes certain disclosures, modifies certain disclosures and adds additional disclosures. The ASU is effective for us on January 1, 2020, and interim periods within that fiscal year. Early adoption is permitted. Certain disclosures in ASU 2018-13 would need to be applied on a retrospective basis and others on a prospective basis. We are currently evaluating the impact this guidance may have on our consolidated financial statements. In June 2018, the FASB issued ASU 2018-07 to expand the scope of ASC Topic 718, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, to include share-based payment transactions for acquiring goods and services from nonemployees. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company concluded after evaluation, that the impact of ASU 2018-07 on our consolidated financial statements and disclosures was de minimis. In February 2017, the FASB issued ASU No. 2017-05, “Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets” (“ASU 2017-05”). ASU 2017-05 is meant to clarify the scope of the original guidance within Subtopic 610-20 that was issued in connection with ASU 2014-09, as defined below, which provides guidance for recognizing gains and losses from the transfer of nonfinancial assets in contracts with noncustomers. ASU 2017-05 also added guidance for partial sales of nonfinancial assets. ASU 2017-05 is effective for our fiscal year ending December 31, 2018 and we are required to adopt ASU 2017-05 concurrent with the adoption of ASU 2014-09. The Company adopted ASU 2017-05 January 1, 2018. The Company concluded after evaluation, that the impact of ASU 2017-05 on our consolidated financial statements and disclosures was de minimis. In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting (“ASU 2017-09”). The FASB issued ASU 2017-09 to clarify and reduce both (i) diversity in practice and (ii) cost and complexity when applying the guidance in Topic 718, to a change to the terms and conditions of a share-based payment award. This guidance became effective for the Company as of January 1, 2018. The amendments in this ASU have been applied prospectively to awards modified after the adoption date. In May 2014, the FASB issued ASU 2014-9, Revenue from Contracts with Customers (Topic 606), to clarify the principles for recognizing revenue. This update provides a comprehensive new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. In September 2017, the FASB issued ASU No. 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842): Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and Rescission of Prior SEC Staff Announcements and Observer Comments. The amendments in ASU No. 2017-13 amends the early adoption date option for certain companies related to the adoption of ASU No. 2014-09 and ASU No. 2016-02. In November 2017, the FASB issued ASU No. 2017-14, Revenue from Contracts with Customers (Topic 606): Income Statement- Reporting Comprehensive Income (Topic 220), Revenue Recognition (Topic 605), which amends certain SEC paragraphs within the FASB Accounting Standards Codification. These standards had the same effective date and transition date of January 1, 2018. The new revenue standard allows for either full retrospective or modified retrospective application. The Company currently does not have any revenue and therefore this update has virtually no effect on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new guidance requires the recognition of lease liabilities, representing future minimum lease payments, on a discounted basis, and corresponding right-of-use assets on a balance sheet for most leases, along with requirements for enhanced disclosures to give financial statement users the ability to assess the amount, timing and uncertainty of cash flows arising from leasing arrangements. In July 2018, the FASB issued ASU 2018-10 and 2018-11 which permit application of the new guidance at the beginning of the year of adoption, recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption, in addition to the method of applying the new guidance retrospectively to each prior reporting period presented. The ASU is effective for us on January 1, 2019. We have concluded the impact of this guidance will be negligible on our consolidated financial statements, given we have no material leases.

Loss per Share

Loss per Share	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Loss per Share	3. Loss per Share Loss per common share is presented under two formats: basic loss per common share and diluted loss per common share. Basic loss per common share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period, plus the potentially dilutive impact of common shares equivalents (e.g. stock options and warrants). Dilutive common share equivalents consist of the incremental common shares issuable upon exercise of stock options and warrants. The following table sets forth the computation of basic and diluted net loss per share (in thousands except per share data): Year Ended December 31, 2018 December 31, 2017 Numerator: Net loss $ (9,888 ) $ (7,046 ) Denominator: Weighted-average common shares, basic 18,942 15,014 Dilutive effect of stock options – – Dilutive effect of warrants – – Incremental dilutive shares – – Weighted-average common shares, dilutived 18,942 15,014 Net loss per share, basic and diluted $ (0.52 ) $ (0.47 ) The following outstanding options and warrants were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect (in thousands): Year Ended December 31, 2018 December 31, 2017 Options to purchase common shares 2,498 2,315 Warrants to purchase common shares - 1,362

Stock options

Stock options	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock options	4. Stock options The Compensation Committee of the Board of Directors administers the Company’s stock option plan. The Compensation Committee designates eligible participants to be included under the plan and approves the number of options to be granted from time to time under the plan. On June 24, 2010, at the Company’s annual meeting, shareholders approved an amendment to the Company’s Stock Option Plan (the “Plan Maximum Amendment”). The Plan Maximum Amendment relates to changing the maximum number of common shares issuable under the stock option plan from a fixed number of 6.7 million to the number of shares that represents twenty-five percent (25%) of the total number of all issued and outstanding common shares. Based upon the current shares outstanding, a maximum of 5.0 million of our common shares are authorized for issuance under the plan. The option exercise price for all options issued under the plan is based on the fair value of the underlying shares on the date of grant. All options vest within three years or less and are exercisable for a period of seven years from the date of grant. The stock option plan, as amended, allows the issuance of Canadian and U.S. dollar grants. A summary of the stock option transactions, for both the Canadian and U.S. dollar grants, through the year ended December 31, 2018 is below. Summary of $CAD Option Activity Share Prices Reported in $CAD Number of Options (in thousands) Range Weighted Average Outstanding and exercisable at December 31, 2016 999 $ 1.62 – 2.43 $ 2.38 Exercised (196 ) 1.89 – 2.43 2.36 Forfeited or expired (91 ) 1.89 – 2.43 2.40 Outstanding and exercisable at December 31, 2017 712 $ 1.89 – 2.43 $ 2.38 Exercised (64 ) 1.62 – 2.43 1.83 Outstanding and exercisable at December 31, 2018 648 $ 2.43 $ 2.43 Summary of $CAD Option Remaining Life Price $CAD Outstanding and Exercisable at December 31, 2018 (in thousands) Weighted Average Remaining Life (years) $ 2.43 648 1.63 Total 648 1.63 Summary of $USD Option Activity Number of Options (in thousands) Range Weighted Average Outstanding and exercisable at December 31, 2016 1,428 $ 0.45 – 3.60 $ 1.93 Granted 341 3.10 – 10.10 5.27 Exercised (163 ) 0.60 – 2.79 1.22 Forfeited or expired (3 ) 2.79 2.79 Outstanding and exercisable at December 31, 2017 1,603 $ 0.45 – 10.10 $ 2.70 Granted 305 8.38 – 12.59 9.23 Exercised (58 ) 1.05 – 3.67 2.06 Outstanding and exercisable at December 31, 2018 1,850 $ 0.45 – 12.59 $ 3.80 Summary of $USD Option Remaining Life Price in US Dollars Number Outstanding and Exercisable at December 31, 2018 (in thousands) Remaining Life (years) $ 0.45 11 0.63 $ 0.54 19 1.38 $ 0.60 17 1.26 $ 0.72 50 1.65 $ 0.96 10 1.60 $ 1.05 93 0.99 $ 1.13 50 3.95 $ 1.23 8 3.86 $ 1.50 7 0.88 $ 1.59 133 2.07 $ 2.11 36 5.00 $ 2.30 4 3.36 $ 2.31 275 2.32 $ 2.35 4 3.59 $ 2.40 8 1.26 $ 2.44 49 4.44 $ 2.45 285 4.51 $ 2.51 4 3.21 $ 2.55 4 2.85 $ 2.69 114 3.00 $ 2.79 22 2.59 $ 2.94 3 1.38 $ 3.10 10 5.26 $ 3.60 3 2.37 $ 3.67 35 5.38 $ 5.10 250 5.49 $ 6.72 21 5.63 $ 8.38 210 6.11 $ 10.10 20 5.88 $ 10.93 85 6.44 $ 12.59 10 6.26 Total 1,850 3.80 Stock compensation expense for the fiscal years ended December 31, 2018 and 2017 was $2.1 million and $2.3 million respectively. These amounts have been included in the general and administrative expenses for the respective periods. The weighted average fair value per share of options granted and or vested during the fiscal years ended December 31, 2018 and 2017 was $9.12 and $5.27, respectively. The intrinsic value (being the difference between the share price at December 31, 2018 and exercise price) of stock options exercisable at December 31, 2018 was $8.6 million. The intrinsic value of options exercised during the fiscal year ended December 31, 2018 was $1.1 million. The fair value of all options vested during the fiscal year ended December 31, 2018 was $2.1 million. The fair values of options granted in fiscal years ended December 31, 2018 and 2017 were estimated on the date the options were granted based on the Black-Scholes option-pricing model, using the following weighted average assumptions for all options with a seven-year expiration: Year Ended December 31, 2018 Year Ended December 31, 2017 Expected dividend 0 % 0 % Risk-free interest rate 2.53– 3.00 % 2.04 – 2.33 % Expected volatility 132 – 151 % 158 – 168 % Expected life 4.5 - 7 years 7 years The Company uses the historical volatility and adjusts for available relevant market information pertaining to the Company’s share price. Modification of Existing Canadian Dollar Denominated Options In 2018, the Company modified the terms of certain options granted to executives and directors by extending the expiration date by a weighted average amount of 2.0 years. The Company recorded option modification expense of approximately $112,000 included in general and administrative expense. The expense was calculated using the Black-Scholes valuation method with a June 7, 2018 exchange rate of $CAD/$USD 0.7715. The following table summarizes the effect of the June 7, 2018 transaction: Number of Options Expiration Date Risk Free Rate Exercise Price $CAD Share Price $CAD Expected Life (Years) Volatility Expense Recognized $USD 648 08/18/2020 1.90 % 2.43 14.14 2.2 76 % 112 648 112 Shareholder rights plan On June 27, 2017, the Company’s shareholders approved a Shareholder Rights Plan Agreement (the "Rights Plan") for the Company. The Rights Plan is to ensure, to the extent possible, that all shareholders of the Corporation are treated fairly and equally in connection with any take-over bid or other acquisition of control of the Corporation. The Rights Plan is designed to require any potential transaction that will result in a person owning, in the aggregate, 20% or more of the outstanding Common Shares to be structured as a formal take-over bid that satisfies certain minimum requirements relating primarily to the manner in which the bid must be made, the minimum number of days the bid must remain open, and the minimum number of shares that must be acquired under the bid. Registration of Certain Common Shares, Options and Warrants (S-1, S-3 & S-8) S-3 Resale On August 11, 2017, the Company filed a Form S-1 (subsequently amended to Form S-3) registration statement with the SEC to register 11.9 million common shares, which includes 1.4 million common shares issuable upon exercise of warrants. The Form S-3 amendment became effective on April 19, 2018 and remains effective. This Form S-3 filing covers shareholders of common shares and warrants from the following transactions:  The Company’s April 2010 private placement of common shares and warrants to purchase common shares;  The Company’s November 2013 private placement of common shares and warrants to purchase common shares;  The Company’s February 2016 private placements of warrants to purchase common shares in lieu of payment for services rendered;  The Company’s May 2016 private placement of common shares; and  The Company’s June 2017 private placement of common shares. S-3 Primary On October 24, 2017, the Company filed a Form S-3 registration statement with the SEC, pursuant to which the Company may offer from time to time, common shares having an aggregate offering price of up to $90.0 million. This Form S-3 became effective on November 3, 2016 and remains in effect. The Company used this Form S-3 to sell shares during a public offering which closed on December 12, 2017, from which the Company raised $21.2 million total gross proceeds. The Company may in the future offer shares for up to an aggregate of the remaining limit of this Form S-3 (approximately $68.8 million). S-8 On October 24, 2017, the Company filed a Form S-8 registration statement with the SEC registering options to purchase 4.0 million of our common shares. The S-8 registration became effective upon filing and remains in effect.

Derivative Liabilities

Derivative Liabilities	12 Months Ended
	Dec. 31, 2018
Summary of Derivative Instruments [Abstract]
Derivative Liabilities	5. Derivative Liabilities The Company's derivative instruments on January 1, 2018 included options to purchase 19,441 common shares, the exercise prices for which are denominated in a currency other than the Company's functional currency, as follows:  Contractor options to purchase 17,394 common shares exercisable at CAD$1.62 per whole common share that expire on April 4, 2018;  Contractor options to purchase 2,047 common shares exercisable at CAD$2.43 per whole common share that expire on May 18, 2018. During the year ended December 31, 2018, all of these derivative options were exercised. This resulted in gross proceeds of $26,109, the issuance of 19,441 common shares and a non-cash, unrealized gain on the extinguishment of the remaining derivative liability of $167,131. During the fiscal years ended December 31, 2011 and 2010, the Company issued 35,892 and 28,796, respectively, options to contractors with a Canadian dollar denominated strike price. Consequently, the Company had derivatives relating to these options since the strike price is denominated in a currency other than the US dollar functional currency of the Company. While there is an exception to this rule for employees in ASU 2010-13 "Compensation-Stock Compensation (Topic 718): Effect of Denominating the exercise price of a share-based payment award in the currency of the market in which the underlying equity security trades", no such exception exists for contractors. These options were marked to market until the earlier of their expiry or exercise. All Canadian denominated options issued to contractors fully vested at issuance and were to expire seven years from date of issuance. The fair value of these options at December 31, 2018 and December 31, 2017 was $0 and $ 167,131 The following is a summary of Canadian denominated contractor option activity for the year ended December 31, 2018 and 2017. Share Prices Reported in $CAD Number of Options Outstanding and Exercisable (in thousands) Weighted Average Exercise Price Outstanding and exercisable at December 31, 2016 40 $ 1.81 Exercised (21 ) 1.90 Forfeited or expired – – Outstanding and exercisable at December 31, 2017 19 $ 1.71 Exercised (19 ) $ 1.71 Outstanding and exercisable at December 31, 2018 – – The following table presents the overall change in derivative liability for the year ended December 31, 2018 and December 31, 2017: (Loss)/Gain (in thousands) on Derivative Value (in thousands) at Derivative Derivative Warrants/Options December 31, Instruments at December 31, 2018 2017 2018 2017 Options (various expiration dates) - 167 167 (134 ) Total - 167 167 (134 )

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	6. Fair Value Measurements The Company has adopted ASC 820 Fair Value Measurements and Disclosure Topic of the FASB. This Topic applies to certain assets and liabilities that are being measured and reported on a fair value basis. The Fair Value Measurements Topic defines fair value, establishes a framework for measuring fair value in accordance with US GAAP, and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. Assets/Liabilities Measured at Fair Value on a Recurring Basis Fair Value Measurement at December 31, (in thousands) Quoted Price in Active Significant Other Significant Level 1 Level 2 Level 3 Total 2018 2017 2018 2017 2018 2017 2018 2017 Assets Cash and cash equivalents 770 (1) 275 (1) 22,011 27,985 - - 22,781 28,260 Liabilities Derivative liabilities - - - 167 - - - 167 (1) The Company held approximately, $770,000 in cash as of December 31, 2018, of which approximately, $121,000 was in Canadian funds (translated into U.S. dollars). As of December 31, 2017, the Company held approximately $275,000, of which approximately 255,000 was in Canadian funds (translated into U.S. dollars).

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity Attributable to Parent [Abstract]
Stockholders' Equity	7. Stockholders’ Equity Authorized capital stock The Company’s authorized capital stock consists of an unlimited number of shares of no-par common shares. Equity financings On June 8, 2017, the Company completed the closing of a non-brokered private placement of 1.9 million common shares for gross proceeds of $7.6 million. Each common share was issued at a price of $4.00. On December 12, 2017, the Company announced the completion of an underwritten public offering of 2.35 million common shares at a public offering price of $8.50 per share. In addition, Fennec issued an additional 135,670 common shares in connection with the partial exercise of the underwriters’ over-allotment option. The approximate total gross proceeds from the offering was $21.2 million. Warrants to Purchase Common Shares At December 31, 2018, the Company had no outstanding warrants to purchase common shares.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions Disclosure	8. Related Party Transactions In the second quarter of 2018, the Company recorded approximately $25 related to the net recovery of short-swing profits from one of the Company’s shareholders under Section 16(b) of the Securities Exchange Act of 1934, as amended. The Company recognized these related party proceeds, net of $7 related legal fees and taxes, as an increase to additional paid-in capital consolidated balance sheet as of December 31, 2018, as well as cash proceeds of approximately $18 as cash provided by financing activities in the consolidated statement of cash flows for the period ended December 31, 2018.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	9. Commitments and Contingencies Oregon Health & Science University Agreement On February 20, 2013, Fennec entered into a new exclusive license agreement with OHSU for exclusive worldwide license rights to intellectual property directed to thiol-based compounds, including STS and their use in oncology (the "New OHSU Agreement"). OHSU will receive certain milestone payments, royalty on net sales for licensed products and a royalty on any consideration received from sublicensing of the licensed technology. The term of the New OHSU Agreement expires on the date of the last to expire claim(s) covered in the patents licensed to Fennec, unless earlier terminated as provided in the agreement. The New OHSU Agreement is terminable by either Fennec or OHSU in the event of a material breach of the agreement by either party after 45 days prior written notice. Fennec also has the right to terminate the New OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the New OHSU Agreement. On May 18, 2015, Fennec negotiated an amendment ("Amendment 1") to the exclusive license agreement with OHSU. Amendment 1 expands the exclusive license agreement signed with OHSU on February 20, 2013 ("OHSU Agreement") to include the use of N-acetylcysteine as a standalone therapy and/or in combination with STS for the prevention of ototoxicity induced by chemotherapeutic agents to treat cancers. Further, Amendment 1 adjusts select milestone payments entered in the OHSU Agreement including but not limited to the royalty rate on net sales for licensed products, royalty rate from sublicensing of the licensed technology and the fee payable upon the regulatory approval of a licensed product. The term of Amendment 1 under the OHSU Agreement expires on the date of the last to expire claim(s) covered in the patents licensed to Fennec or 8 years, whichever is later. In the event a licensed product obtains regulatory approval and is covered by the Orphan Drug Designation, the parties will in good faith amend the term of the agreement. STS is currently protected by methods of use patents that the Company exclusively licensed from OHSU that expire in Europe in 2021 and are currently pending in the United States. The New OHSU Agreement is terminable by either Fennec or OHSU in the event of a material breach of the agreement by either party after 45 days prior written notice. Fennec also has the right to terminate the New OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the New OHSU Agreement. Executive Severance In the event of his termination with us other than for cause, we will be obligated to pay Mr. Raykov a one-time severance payment equal to twelve months of salary (currently $350,000). In the event of his termination with us other than for cause, we will be obligated to pay Mr. Andrade a one-time severance payment equal to six months of salary (currently $125,000).

Subsequent events

Subsequent events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events On February 1, 2019, the Company’s wholly owned subsidiary of Fennec Pharmaceuticals Inc. entered into a Loan and Security Agreement (the “Loan and Security Agreement”) with Bridge Bank, a division of Western Alliance Bank, an Arizona corporation (the “Bank”), pursuant to which the Bank agreed to loan $12.5 million to Fennec Pharmaceuticals, Inc., to be made available upon New Drug Application (“NDA”) approval of PEDMARK by no later than September 30, 2020. The proceeds from the loan will be used for working capital purposes and to fund general business requirements in accordance with the terms of the Loan and Security Agreement. Interest under the Term Loans shall bear interest, on the outstanding daily balance thereof, at a floating per annum rate equal to the Effective Interest Rate (as defined in the Loan and Security Agreement) which is equal to the sum of the Prime Rate published in the Wall Street Journal (currently 5.50%) plus one percent (1.00%). The debt facility is to have interest-only monthly payments due for the first eighteen months from the funding date and then monthly principal and interest payments are due through the remainder of the term which has a maturity date of October 1, 2023. In connection with the facility, Fennec has agreed to grant Bridge Bank a warrant to purchase up to 39,130 common shares at an exercise price of $6.80 per common share, for a term of ten years from the date of issuance, subject to early termination under certain conditions. Management has evaluated subsequent events through March 15, 2019, the date the financial statements were available to be issued and there are no additional subsequent events that would require adjustment to or disclosure in the statements.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	11. Income Taxes The Company operates in both U.S. and Canadian tax jurisdictions. Its income is subject to varying rates of tax and losses incurred in one jurisdiction cannot be used to offset income taxes payable in another. A reconciliation of the combined Canadian federal and provincial income tax rate with the Company’s effective tax rate is as follows (in thousands except for percentage rates): Year Ended December 31, Year Ended December 31, 2018 2017 Domestic (loss)/gain $ (7,702 ) $ (5,277 ) Foreign loss (2,145 ) (1,769 ) Loss before income taxes (9,847 ) (7,046 ) Expected statutory rate (recovery) 26.50 % 26.50 % Expected provision for (recovery of) income tax (2,609 ) (1,867 ) Permanent differences 512 636 Change in valuation allowance 2,042 328 Effect of foreign exchange rate differences – – Effect of change in future enacted tax rates – 843 Tax credits and other adjustments – (3 ) Effect of tax rate changes and other 55 63 Provision for income taxes $ - $ – The Canadian statutory come tax rate of 26.0 percent is comprised of federal income tax at approximately 15.0 percent and provincial income tax at approximately 11.0 percent. The primary temporary differences which gave rise to future income taxes (recovery) at December 31, 2018 and December 31, 2017: December 31, 2018 December 31, 2017 Future tax assets: SR&ED expenditures $ 2,195 $ 2,195 Income tax loss carryforwards 21,452 19,431 Non-refundable investment tax credits 1,250 1,263 Share issue costs 45 – Accrued expenses – – Fixed and intangible assets 1,065 1,031 Reserves 13 – 26,020 23,920 Less: valuation allowance (26,020 ) (23,920 ) Net future tax assets $ – $ – Tax Cuts and Jobs Act On December 22, 2017, the United States government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and jobs Act (the “Tax Act”). The Tax Act reduces the corporate tax rate to 21%, effective January 1, 2018. The Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 (“SAB 118”) on December 23, 2017. SAB 118 provides a one-year measurement period from a registrant’s reporting period that includes the United States Tax Act’s enactment date to allow the registrant sufficient time to obtain, prepare and analyze information to complete the accounting required under ASC 740. The ultimate impact of the Tax Act on our reported results may differ from the estimates provided herein, possibly material, due to, among other things, changes in interpretations and assumptions we have made, guidance that may be issued, and other actions we may take as a result of the Tax Act different from presently contemplated. There are no current income taxes owed, nor are any income taxes expected to be owed in the near term. At December 31, 2018 the Company has unclaimed Scientific Research and Experimental Development ("SR&ED") expenditures, income tax loss carry-forwards and non-refundable investment tax credits. The unclaimed amounts and their expiry dates are as listed below: Federal Province/ State SR&ED expenditures (no expiry) $ 8,283 $ - Income tax loss carryforwards (expiry date): 2019 - 1,455 2020 - 4,768 2021 26 8,885 2022 233 4,219 2023 133 4,164 2024 1,536 2,116 2025 4,795 700 2026 20,562 12,454 2027 8,340 4,764 2028 10,840 7,314 2029 8,502 7,003 2030 2,608 2,741 2031 3,378 3,448 2032 3,491 4,370 2033 1,789 3,156 2034 1,812 1,606 2035 1,804 861 2036 2,208 1,189 2037 4,641 2,882 2038 5,655 5,655 No expiration 2,160 - Investment tax credits (expiry date): 2019 96 2020 55 2021 548 2022 399 2023 178 2024 199 2025 86 2026 90 2027 50

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The consolidated financial statements include the accounts of Fennec and of all its wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated upon consolidation.
Use of estimates	Use of estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include the valuation of derivative warrant liability and the valuation of stock-based compensation. Actual results could differ from those estimates.
Cash and cash equivalents	Cash and Cash Equivalents Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less. The Company places its cash and cash equivalents in investments held by highly rated financial institutions in accordance with its investment policy designed to protect the principal investment. At December 31, 2018, the Company had $22.8 million in cash and money market accounts (2017- $28.3 million). Money market investments typically have minimal risks. The Company has not experienced any loss or write-down of its money market investments.
Financial instruments	Financial instruments Financial instruments recognized on the balance sheets at December 31, 2018 and December 31, 2017 consist of cash and cash equivalents, accounts payable, accrued liabilities and derivative instruments, the carrying values of which, with the exception of the derivative instruments, approximate fair value due to their relatively short time to maturity. The Company does not hold or issue financial instruments for trading. The derivative liabilities are carried at fair value. The Company’s investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments, when made, are made in U.S. or Canadian bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper. The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. As the main purpose of the Company is research and development, the Company has chosen to avoid investments of a trading or speculative nature.
Common stock and warrants	Common shares and warrants The Company has warrants outstanding to purchase common shares that were denominated in both United States dollars (“USD”) and Canadian dollars (“CAD”), which resulted in the Company having warrants outstanding that were denominated outside of the Company’s U.S. dollar functional currency. The Company’s outstanding warrants denominated in Canadian dollars were not considered to be indexed to the Company’s own stock and should therefore be treated as derivative financial instruments and recorded at their fair value as a liability. During the year ended December 31, 2018, all warrants accounted for as derivatives were exercised. These exercises reduced the derivative liability to $0 as of December 31, 2018. $167,000 $134,000 during the year ended December 31, 2017 .
Revenue recognition	Revenue recognition At this time, the Company does not have any revenue.
Research and development costs and investment tax credits	Research and development costs and investment tax credits Research costs, including employee compensation, laboratory fees, lab supplies, and research and testing performed under contract by third parties, are expensed as incurred. Development costs, including drug substance costs, clinical study expenses and regulatory expenses are expensed as incurred. Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made, and their realization is reasonably assured. They are applied to reduce related capital costs and research and development expenses in the year recognized.
Income taxes	Income taxes The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December 31, 2018, we maintained a full valuation allowance against our deferred tax assets. The provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740-10, Uncertainty in Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.
Foreign currency translation	Foreign currency translation The U.S. dollar is the functional currency for the Company’s consolidated operations. All gains and losses from currency translations are included in results of operations.
Earnings/(Loss) per share	Loss per share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the year. Diluted net earnings per share is computed using the same method, except the weighted average number of common shares outstanding includes convertible debentures, stock options and warrants, if dilutive, as determined using the if-converted method and treasury methods. Accordingly, options to purchase 2.5 million of our common shares at December 31, 2018, were not included in earnings per share. Such options would have an antidilutive effect. In 2017, options to purchase 2.3 million common shares and warrants to purchase 1.4 million of our common shares were excluded from the computation of earnings per share as their inclusion would have been antidilutive.
New accounting pronouncements	Recent accounting pronouncements In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 removes certain disclosures, modifies certain disclosures and adds additional disclosures. The ASU is effective for us on January 1, 2020, and interim periods within that fiscal year. Early adoption is permitted. Certain disclosures in ASU 2018-13 would need to be applied on a retrospective basis and others on a prospective basis. We are currently evaluating the impact this guidance may have on our consolidated financial statements. In June 2018, the FASB issued ASU 2018-07 to expand the scope of ASC Topic 718, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, to include share-based payment transactions for acquiring goods and services from nonemployees. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company concluded after evaluation, that the impact of ASU 2018-07 on our consolidated financial statements and disclosures was de minimis. In February 2017, the FASB issued ASU No. 2017-05, “Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets” (“ASU 2017-05”). ASU 2017-05 is meant to clarify the scope of the original guidance within Subtopic 610-20 that was issued in connection with ASU 2014-09, as defined below, which provides guidance for recognizing gains and losses from the transfer of nonfinancial assets in contracts with noncustomers. ASU 2017-05 also added guidance for partial sales of nonfinancial assets. ASU 2017-05 is effective for our fiscal year ending December 31, 2018 and we are required to adopt ASU 2017-05 concurrent with the adoption of ASU 2014-09. The Company adopted ASU 2017-05 January 1, 2018. The Company concluded after evaluation, that the impact of ASU 2017-05 on our consolidated financial statements and disclosures was de minimis. In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting (“ASU 2017-09”). The FASB issued ASU 2017-09 to clarify and reduce both (i) diversity in practice and (ii) cost and complexity when applying the guidance in Topic 718, to a change to the terms and conditions of a share-based payment award. This guidance became effective for the Company as of January 1, 2018. The amendments in this ASU have been applied prospectively to awards modified after the adoption date. In May 2014, the FASB issued ASU 2014-9, Revenue from Contracts with Customers (Topic 606), to clarify the principles for recognizing revenue. This update provides a comprehensive new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. In September 2017, the FASB issued ASU No. 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842): Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and Rescission of Prior SEC Staff Announcements and Observer Comments. The amendments in ASU No. 2017-13 amends the early adoption date option for certain companies related to the adoption of ASU No. 2014-09 and ASU No. 2016-02. In November 2017, the FASB issued ASU No. 2017-14, Revenue from Contracts with Customers (Topic 606): Income Statement- Reporting Comprehensive Income (Topic 220), Revenue Recognition (Topic 605), which amends certain SEC paragraphs within the FASB Accounting Standards Codification. These standards had the same effective date and transition date of January 1, 2018. The new revenue standard allows for either full retrospective or modified retrospective application. The Company currently does not have any revenue and therefore this update has virtually no effect on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new guidance requires the recognition of lease liabilities, representing future minimum lease payments, on a discounted basis, and corresponding right-of-use assets on a balance sheet for most leases, along with requirements for enhanced disclosures to give financial statement users the ability to assess the amount, timing and uncertainty of cash flows arising from leasing arrangements. In July 2018, the FASB issued ASU 2018-10 and 2018-11 which permit application of the new guidance at the beginning of the year of adoption, recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption, in addition to the method of applying the new guidance retrospectively to each prior reporting period presented. The ASU is effective for us on January 1, 2019. We have concluded the impact of this guidance will be negligible on our consolidated financial statements, given we have no material leases.

Loss per Share (Tables)

Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of basic and diluted net loss per share (in thousands except per share data): Year Ended December 31, 2018 December 31, 2017 Numerator: Net loss $ (9,888 ) $ (7,046 ) Denominator: Weighted-average common shares, basic 18,942 15,014 Dilutive effect of stock options – – Dilutive effect of warrants – – Incremental dilutive shares – – Weighted-average common shares, dilutived 18,942 15,014 Net loss per share, basic and diluted $ (0.52 ) $ (0.47 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following outstanding options and warrants were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect (in thousands): Year Ended December 31, 2018 December 31, 2017 Options to purchase common shares 2,498 2,315 Warrants to purchase common shares - 1,362

Stock options (Tables)

Stock options (Tables)	12 Months Ended
	Dec. 31, 2018
Fair values of options granted using weighted average assumptions	The fair values of options granted in fiscal years ended December 31, 2018 and 2017 were estimated on the date the options were granted based on the Black-Scholes option-pricing model, using the following weighted average assumptions for all options with a seven-year expiration: Year Ended December 31, 2018 Year Ended December 31, 2017 Expected dividend 0 % 0 % Risk-free interest rate 2.53– 3.00 % 2.04 – 2.33 % Expected volatility 132 – 151 % 158 – 168 % Expected life 4.5 - 7 years 7 years
Currency, Canadian Dollar [Member]
Options granted under the stock option plan are exercisable	Summary of $CAD Option Activity Share Prices Reported in $CAD Number of Options (in thousands) Range Weighted Average Outstanding and exercisable at December 31, 2016 999 $ 1.62 – 2.43 $ 2.38 Exercised (196 ) 1.89 – 2.43 2.36 Forfeited or expired (91 ) 1.89 – 2.43 2.40 Outstanding and exercisable at December 31, 2017 712 $ 1.89 – 2.43 $ 2.38 Exercised (64 ) 1.62 – 2.43 1.83 Outstanding and exercisable at December 31, 2018 648 $ 2.43 $ 2.43
Options reinstated agreement either expired and cancelled prior to the agreed severance	Summary of $CAD Option Remaining Life Price $CAD Outstanding and Exercisable at December 31, 2018 (in thousands) Weighted Average Remaining Life (years) $ 2.43 648 1.63 Total 648 1.63
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes the effect of the June 7, 2018 transaction: Number of Options Expiration Date Risk Free Rate Exercise Price $CAD Share Price $CAD Expected Life (Years) Volatility Expense Recognized $USD 648 08/18/2020 1.90 % 2.43 14.14 2.2 76 % 112 648 112
Currency, U.S. Dollar [Member]
Options granted under the stock option plan are exercisable	Summary of $USD Option Activity Number of Options (in thousands) Range Weighted Average Outstanding and exercisable at December 31, 2016 1,428 $ 0.45 – 3.60 $ 1.93 Granted 341 3.10 – 10.10 5.27 Exercised (163 ) 0.60 – 2.79 1.22 Forfeited or expired (3 ) 2.79 2.79 Outstanding and exercisable at December 31, 2017 1,603 $ 0.45 – 10.10 $ 2.70 Granted 305 8.38 – 12.59 9.23 Exercised (58 ) 1.05 – 3.67 2.06 Outstanding and exercisable at December 31, 2018 1,850 $ 0.45 – 12.59 $ 3.80
Options reinstated agreement either expired and cancelled prior to the agreed severance	Summary of $USD Option Remaining Life Price in US Dollars Number Outstanding and Exercisable at December 31, 2018 (in thousands) Remaining Life (years) $ 0.45 11 0.63 $ 0.54 19 1.38 $ 0.60 17 1.26 $ 0.72 50 1.65 $ 0.96 10 1.60 $ 1.05 93 0.99 $ 1.13 50 3.95 $ 1.23 8 3.86 $ 1.50 7 0.88 $ 1.59 133 2.07 $ 2.11 36 5.00 $ 2.30 4 3.36 $ 2.31 275 2.32 $ 2.35 4 3.59 $ 2.40 8 1.26 $ 2.44 49 4.44 $ 2.45 285 4.51 $ 2.51 4 3.21 $ 2.55 4 2.85 $ 2.69 114 3.00 $ 2.79 22 2.59 $ 2.94 3 1.38 $ 3.10 10 5.26 $ 3.60 3 2.37 $ 3.67 35 5.38 $ 5.10 250 5.49 $ 6.72 21 5.63 $ 8.38 210 6.11 $ 10.10 20 5.88 $ 10.93 85 6.44 $ 12.59 10 6.26 Total 1,850 3.80

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Summary of Derivative Instruments [Abstract]
Unrealized Gain on Derivatives	The following is a summary of Canadian denominated contractor option activity for the year ended December 31, 2018 and 2017. Share Prices Reported in $CAD Number of Options Outstanding and Exercisable (in thousands) Weighted Average Exercise Price Outstanding and exercisable at December 31, 2016 40 $ 1.81 Exercised (21 ) 1.90 Forfeited or expired – – Outstanding and exercisable at December 31, 2017 19 $ 1.71 Exercised (19 ) $ 1.71 Outstanding and exercisable at December 31, 2018 – –
Schedule of Other Share-based Compensation, Activity	The following table presents the overall change in derivative liability for the year ended December 31, 2018 and December 31, 2017: (Loss)/Gain (in thousands) on Derivative Value (in thousands) at Derivative Derivative Warrants/Options December 31, Instruments at December 31, 2018 2017 2018 2017 Options (various expiration dates) - 167 167 (134 ) Total - 167 167 (134 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Assets/Liabilities Measured at Fair Value on Recurring Basis	Assets/Liabilities Measured at Fair Value on a Recurring Basis Fair Value Measurement at December 31, (in thousands) Quoted Price in Active Significant Other Significant Level 1 Level 2 Level 3 Total 2018 2017 2018 2017 2018 2017 2018 2017 Assets Cash and cash equivalents 770 (1) 275 (1) 22,011 27,985 - - 22,781 28,260 Liabilities Derivative liabilities - - - 167 - - - 167 (1) The Company held approximately, $770,000 in cash as of December 31, 2018, of which approximately, $121,000 was in Canadian funds (translated into U.S. dollars). As of December 31, 2017, the Company held approximately $275,000, of which approximately 255,000 was in Canadian funds (translated into U.S. dollars).

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	A reconciliation of the combined Canadian federal and provincial income tax rate with the Company’s effective tax rate is as follows (in thousands except for percentage rates): Year Ended December 31, Year Ended December 31, 2018 2017 Domestic (loss)/gain $ (7,702 ) $ (5,277 ) Foreign loss (2,145 ) (1,769 ) Loss before income taxes (9,847 ) (7,046 ) Expected statutory rate (recovery) 26.50 % 26.50 % Expected provision for (recovery of) income tax (2,609 ) (1,867 ) Permanent differences 512 636 Change in valuation allowance 2,042 328 Effect of foreign exchange rate differences – – Effect of change in future enacted tax rates – 843 Tax credits and other adjustments – (3 ) Effect of tax rate changes and other 55 63 Provision for income taxes $ - $ –
Summary of Tax Credit Carryforwards [Table Text Block]	The primary temporary differences which gave rise to future income taxes (recovery) at December 31, 2018 and December 31, 2017: December 31, 2018 December 31, 2017 Future tax assets: SR&ED expenditures $ 2,195 $ 2,195 Income tax loss carryforwards 21,452 19,431 Non-refundable investment tax credits 1,250 1,263 Share issue costs 45 – Accrued expenses – – Fixed and intangible assets 1,065 1,031 Reserves 13 – 26,020 23,920 Less: valuation allowance (26,020 ) (23,920 ) Net future tax assets $ – $ – There are no current income taxes owed, nor are any income taxes expected to be owed in the near term. At December 31, 2018 the Company has unclaimed Scientific Research and Experimental Development ("SR&ED") expenditures, income tax loss carry-forwards and non-refundable investment tax credits. The unclaimed amounts and their expiry dates are as listed below: Federal Province/ State SR&ED expenditures (no expiry) $ 8,283 $ - Income tax loss carryforwards (expiry date): 2019 - 1,455 2020 - 4,768 2021 26 8,885 2022 233 4,219 2023 133 4,164 2024 1,536 2,116 2025 4,795 700 2026 20,562 12,454 2027 8,340 4,764 2028 10,840 7,314 2029 8,502 7,003 2030 2,608 2,741 2031 3,378 3,448 2032 3,491 4,370 2033 1,789 3,156 2034 1,812 1,606 2035 1,804 861 2036 2,208 1,189 2037 4,641 2,882 2038 5,655 5,655 No expiration 2,160 - Investment tax credits (expiry date): 2019 96 2020 55 2021 548 2022 399 2023 178 2024 199 2025 86 2026 90 2027 50

Nature of Business and Liquid_2

Nature of Business and Liquidity- Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Feb. 01, 2019	Dec. 31, 2018	Dec. 31, 2017
Going Concern [Line Items]
Net Cash Provided by (Used in) Operating Activities		$ (7,826)	$ (3,641)
Retained Earnings (Accumulated Deficit)		(131,256)	(121,368)
Operating Income (Loss)		$ (10,409)	$ (6,951)
Bridge Bank [Member] | Loan and Security Agreement [Member]
Going Concern [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.00%
Bridge Bank [Member] | Loan and Security Agreement [Member] | Term Loan [Member] | Subsequent Event [Member]
Going Concern [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 12,500
Shares, Issued	39,130
Shares Issued, Price Per Share	$ 6.80
Debt Instrument, Basis Spread on Variable Rate	5.50%
Debt Instrument, Interest Rate, Stated Percentage	1.00%

Significant Accounting Polici_3

Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands, shares in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Summary Of Significant Accounting Policies [Line Items]
Money market investments	$ 22,800	$ 28,300
Derivative Liability, Current	0	167
Unrealized Gain (Loss) on Derivatives	$ 167	$ (134)
Employee Stock Option [Member]
Summary Of Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2.5	2.3
Warrant [Member]
Summary Of Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		1.4

Loss per Share (Schedule of Ear

Loss per Share (Schedule of Earnings Per Share, Basic and Diluted) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Numerator:
Net loss	$ (9,888)	$ (7,046)
Denominator:
Weighted-average common shares, basic	18,942	15,014
Incremental dilutive shares	0	0
Weighted-average common shares, dilutived	18,942	15,014
Net loss per share, basic and diluted	$ (0.52)	$ (0.47)
Warrant [Member]
Denominator:
Incremental dilutive shares	0	0
Employee Stock Option [Member]
Denominator:
Incremental dilutive shares	0	0

Loss per Share (warrants were e

Loss per Share (warrants were excluded from the computation of basic and diluted net loss per share) (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,498	2,315
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	1,362

Stock Options (Options Granted

Stock Options (Options Granted Under The Stock Option Plan Exercisable In Canadian Dollars And U.S Dollars) (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Weighted Average Exercise Price Outstanding and Exercisable at Beginning	$ 1.71	$ 1.81
Weighted- Average Exercised	1.71	1.90
Weighted- Average Forfeited or expired		0
Weighted Average Exercise Price Outstanding and Exercisable at Ending	$ 0	$ 1.71
Currency, Canadian Dollar [Member]
Number of Options Outstanding and Exercisable at Beginning	712	999
Number of Options Exercised	(64)	(196)
Number of Options Forfeited or expired		(91)
Number of Options Outstanding and Exercisable at Ending	648	712
Outstanding and Exercisable Range	$ 2.43
Weighted Average Exercise Price Outstanding and Exercisable at Beginning	2.38	$ 2.38
Weighted- Average Exercised	1.83	2.36
Weighted- Average Forfeited or expired		2.40
Weighted Average Exercise Price Outstanding and Exercisable at Ending	2.43	2.38
Currency, Canadian Dollar [Member] | Minimum [Member]
Outstanding and Exercisable Range	1.89	1.62
Exercised Range	1.62	1.89
Forfeited or expired Range		1.89
Outstanding and Exercisable Range		1.89
Currency, Canadian Dollar [Member] | Maximum [Member]
Outstanding and Exercisable Range	2.43	2.43
Exercised Range	$ 2.43	2.43
Forfeited or expired Range		2.43
Outstanding and Exercisable Range		$ 2.43
Currency, U.S. Dollar [Member]
Number of Options Outstanding and Exercisable at Beginning	1,603	1,428
Number of Options Granted	305	341
Number of Options Exercised	(58)	(163)
Number of Options Forfeited or expired		(3)
Number of Options Outstanding and Exercisable at Ending	1,850	1,603
Forfeited or expired Range		$ 2.79
Weighted Average Exercise Price Outstanding and Exercisable at Beginning	$ 2.70	1.93
Weighted- Average Granted	9.23	5.27
Weighted- Average Exercised	2.06	1.22
Weighted- Average Forfeited or expired		2.79
Weighted Average Exercise Price Outstanding and Exercisable at Ending	3.80	2.70
Currency, U.S. Dollar [Member] | Minimum [Member]
Outstanding and Exercisable Range	0.45	0.45
Granted Range	8.38	3.10
Exercised Range	1.05	0.60
Forfeited or expired Range	0.45
Outstanding and Exercisable Range		0.45
Currency, U.S. Dollar [Member] | Maximum [Member]
Outstanding and Exercisable Range	10.10	3.60
Granted Range	12.59	10.10
Exercised Range	3.67	2.79
Forfeited or expired Range	$ 12.59
Outstanding and Exercisable Range		$ 10.10

Stock options (Price In Canadia

Stock options (Price In Canadian Dollars) (Details) - Currency, Canadian Dollar [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number Outstanding and Exercisable	648	712	999
Weighted Average Remaining Life (years)	1 year 7 months 17 days
Price In Canadian Dollars 2.43 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price	$ 2.43
Number Outstanding and Exercisable	648
Weighted Average Remaining Life (years)	1 year 7 months 17 days

Stock Options (Price In US Doll

Stock Options (Price In US Dollars) (Details) - Currency, U.S. Dollar [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number Outstanding and Exercisable	1,850	1,603	1,428
Remaining life (years)	3 years 9 months 18 days
Price In Us Dollars 0.45 [Member]
Price in US Dollars	$ 0.45
Number Outstanding and Exercisable	11
Remaining life (years)	7 months 17 days
Price In Us Dollars 0.54 [Member]
Price in US Dollars	$ 0.54
Number Outstanding and Exercisable	19
Remaining life (years)	1 year 4 months 17 days
Price In Us Dollars 0.60 [Member]
Price in US Dollars	$ 0.60
Number Outstanding and Exercisable	17
Remaining life (years)	1 year 3 months 4 days
Price In Us Dollars 0.72 [Member]
Price in US Dollars	$ 0.72
Number Outstanding and Exercisable	50
Remaining life (years)	1 year 7 months 24 days
Price In Us Dollars 0.96 [Member]
Price in US Dollars	$ 0.96
Number Outstanding and Exercisable	10
Remaining life (years)	1 year 7 months 6 days
Price In Us Dollars 1.05 [Member]
Price in US Dollars	$ 1.05
Number Outstanding and Exercisable	93
Remaining life (years)	11 months 26 days
Price In Us Dollars 1.13 [Member]
Price in US Dollars	$ 1.13
Number Outstanding and Exercisable	50
Remaining life (years)	3 years 11 months 12 days
Price In Us Dollars 1.23 [Member]
Price in US Dollars	$ 1.23
Number Outstanding and Exercisable	8
Remaining life (years)	3 years 10 months 10 days
Price In Us Dollars 1.50 [Member]
Price in US Dollars	$ 1.50
Number Outstanding and Exercisable	7
Remaining life (years)	10 months 17 days
Price In Us Dollars 1.59 [Member]
Price in US Dollars	$ 1.59
Number Outstanding and Exercisable	133
Remaining life (years)	2 years 25 days
Price In Us Dollars 2.11 [Member]
Price in US Dollars	$ 2.11
Number Outstanding and Exercisable	36
Remaining life (years)	5 years
Price In Us Dollars 2.30 [Member]
Price in US Dollars	$ 2.30
Number Outstanding and Exercisable	4
Remaining life (years)	3 years 4 months 10 days
Price In Us Dollars 2.31 [Member]
Price in US Dollars	$ 2.31
Number Outstanding and Exercisable	275
Remaining life (years)	2 years 3 months 25 days
Price In Us Dollars 2.35 [Member]
Price in US Dollars	$ 2.35
Number Outstanding and Exercisable	4
Remaining life (years)	3 years 7 months 2 days
Price In Us Dollars 2.40 [Member]
Price in US Dollars	$ 2.40
Number Outstanding and Exercisable	8
Remaining life (years)	1 year 3 months 4 days
Price In Us Dollars 2.44 [Member]
Price in US Dollars	$ 2.44
Number Outstanding and Exercisable	49
Remaining life (years)	4 years 5 months 8 days
Price In Us Dollars 2.45 [Member]
Price in US Dollars	$ 2.45
Number Outstanding and Exercisable	285
Remaining life (years)	4 years 6 months 4 days
Price In Us Dollars 2.51 [Member]
Price in US Dollars	$ 2.51
Number Outstanding and Exercisable	4
Remaining life (years)	3 years 2 months 16 days
Price In Us Dollars 2.55 [Member]
Price in US Dollars	$ 2.55
Number Outstanding and Exercisable	4
Remaining life (years)	2 years 10 months 6 days
Price In Us Dollars 2.69 [Member]
Price in US Dollars	$ 2.69
Number Outstanding and Exercisable	114
Remaining life (years)	3 years
Price In Us Dollars 2.79 [Member]
Price in US Dollars	$ 2.79
Number Outstanding and Exercisable	22
Remaining life (years)	2 years 7 months 2 days
Price In Us Dollars 2.94 [Member]
Price in US Dollars	$ 2.94
Number Outstanding and Exercisable	3
Remaining life (years)	1 year 4 months 17 days
Price In Us Dollars 3.10 [Member]
Price in US Dollars	$ 3.10
Number Outstanding and Exercisable	10
Remaining life (years)	5 years 3 months 4 days
Price In Us Dollars 3.60 [Member]
Price in US Dollars	$ 3.60
Number Outstanding and Exercisable	3
Remaining life (years)	2 years 4 months 13 days
Price In Us Dollars 3.67 [Member]
Price in US Dollars	$ 3.67
Number Outstanding and Exercisable	35
Remaining life (years)	5 years 4 months 17 days
Price In Us Dollars 5.10 [Member]
Price in US Dollars	$ 5.10
Number Outstanding and Exercisable	250
Remaining life (years)	5 years 5 months 26 days
Price In Us Dollars 6.72 [Member]
Price in US Dollars	$ 6.72
Number Outstanding and Exercisable	21
Remaining life (years)	5 years 7 months 17 days
Price In Us Dollars 8.38 [Member]
Price in US Dollars	$ 8.38
Number Outstanding and Exercisable	210
Remaining life (years)	6 years 1 month 10 days
Price In Us Dollars 10.10 [Member]
Price in US Dollars	$ 10.10
Number Outstanding and Exercisable	20
Remaining life (years)	5 years 10 months 17 days
Price In Us Dollars 10.93 [Member]
Price in US Dollars	$ 10.93
Number Outstanding and Exercisable	85
Remaining life (years)	6 years 5 months 8 days
Price In Us Dollars 12.59 [Member]
Price in US Dollars	$ 12.59
Number Outstanding and Exercisable	10
Remaining life (years)	6 years 3 months 4 days

Stock options (Options Were Gra

Stock options (Options Were Granted Based On The Black Scholes Option Pricing Model) (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Expected dividend	0.00%	0.00%
Expected life		7 years
Minimum [Member]
Risk-free interest rate	2.53%	2.04%
Expected volatility	132.00%	158.00%
Expected life	4 years 6 months
Maximum [Member]
Risk-free interest rate	3.00%	2.33%
Expected volatility	151.00%	168.00%
Expected life	7 years

Stock options (Modification of

Stock options (Modification of Existing Canadian Dollar Denominated Options) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)shares	Dec. 31, 2017	Dec. 31, 2018$ / shares
Expected Life (Years)		7 years
Executives And Directors [Member] | Currency, Canadian Dollar [Member]
Number of Options | shares	648
Expense Recognized | $	$ 112
Executives And Directors [Member] | Stock Option Grant One [Member] | Currency, Canadian Dollar [Member]
Number of Options | shares	648
Expiration Date	Aug. 18, 2020
Risk free rate	1.90%
Exercise Price | $ / shares			$ 2.43
Share Price | $ / shares			$ 14.14
Expected Life (Years)	2 years 2 months 12 days
Volatility Rate	76.00%
Expense Recognized | $	$ 112

Stock options - Additional Info

Stock options - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Oct. 24, 2017	Aug. 11, 2017	Jun. 24, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 8,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	1,100
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 2,100
Description of Difference between Reported Amount and Reporting Currency Denominated Amount	exchange rate of $CAD/$USD 0.7715
Number Of Common Shares Registered				11.9
Registration Payment Arrangement, Maximum Potential Consideration	$ 68,800
Proceeds from Registration Payment Arrangement	$ 21,200
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number			4
S Registration Of Common Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Registration Payment Arrangement, Maximum Potential Consideration			$ 90,000
Canadian Dollar Denominated Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Description and Terms	the Company modified the terms of certain options granted to executives and directors by extending the expiration date by a weighted average amount of 2.0 years
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 2,100	$ 2,300
Stock or Unit Option Plan Expense	$ 112,000
Plan Maximum Amendment [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issuable under Stock Option Plan					5
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issuable under Stock Option Plan					6.7
Percentage Of Total Number Of Share Issued and Outstanding	25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 9.12	$ 5.27

Derivative Liabilities (Contrac

Derivative Liabilities (Contractor Option Activity) (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Stock Options Issuance Outstanding at Beginning	19	40
Stock Options Issuance Exercised	(19)	(21)
Stock Options Issuance Forfeited and expired		0
Stock Options Issuance Outstanding at Ending	0	19
Weighted Average Exercise Price Outstanding and Exercisable at Beginning	$ 1.71	$ 1.81
Weighted- Average Exercised	1.71	1.90
Weighted- Average Forfeited or expired		0
Weighted Average Exercise Price Outstanding and Exercisable at Ending	$ 0	$ 1.71

Derivative Liabilities (Fair Va

Derivative Liabilities (Fair Value Liability) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Gain/(Loss) on Derivative Instruments
Derivative Liability	$ 0	$ 167
Gain/(loss) on Derivative Instruments	167	(134)
Options [Member]
Gain/(Loss) on Derivative Instruments
Derivative Liability	0	167
Gain/(loss) on Derivative Instruments	$ 167	$ (134)

Derivative Liabilities - Additi

Derivative Liabilities - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2011	Dec. 31, 2010
Derivative [Line Items]
Proceeds from Stock Options Exercised	$ 210,000	$ 563,000
Common Stock, Shares, Issued	19,896	18,411
Derivative Liability	$ 0	$ 167,000
Unrealized Gain (Loss) on Derivatives	$ 167,000	(134,000)
Invester Option [Member]
Derivative [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	19,441
Derivative Instrument Option Activity [Member]
Derivative [Line Items]
Proceeds from Stock Options Exercised	$ 26,109
Common Stock, Shares, Issued	19,441
Derivative Liability	$ 167,000
Options [Member]
Derivative [Line Items]
Derivative Liability	0	167,131,000
Canadian Dollar [Member]
Derivative [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number			35,892	28,796
Options To Contractors [Member]
Derivative [Line Items]
Unrealized Gain (Loss) on Derivatives	$ 167,131,000	$ 133,697,000
Contractor Options Expire On April 4, 2018 [Member]
Derivative [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.62
Class of Warrant or Right, Outstanding	17,394
Contractor Options Expire On May 18, 2018 [Member]
Derivative [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.43
Class of Warrant or Right, Outstanding	2,047

Fair Value Measurements (Assets

Fair Value Measurements (Assets/Liabilities Measured at Fair Value on Recurring Basis) (Details) - USD ($) $ in Thousands		Dec. 31, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents		$ 22,781	$ 28,260
Derivative liabilities		0	167
Quoted Price in Active Markets for Identical Instruments Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents	[1]	770	275
Derivative liabilities		0	0
Significant Other Observable Inputs Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents		22,011	27,985
Derivative liabilities		0	167
Significant Unobservable Inputs Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents		0	0
Derivative liabilities		$ 0	$ 0
[1]	The Company held approximately, $770,000 in cash as of December 31, 2018, of which approximately, $121,000 was in Canadian funds (translated into U.S. dollars). As of December 31, 2017, the Company held approximately $275,000, of which approximately 255,000 was in Canadian funds (translated into U.S. dollars).

Fair Value Measurements (Asse_2

Fair Value Measurements (Assets/Liabilities Measured at Fair Value on Recurring Basis) (Parenthetical) (Details) $ in Thousands, $ in Thousands	Dec. 31, 2018USD ($)	Dec. 31, 2018CAD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2017CAD ($)
Assumptions used to Determine Fair Value Options [Line Items]
Cash	$ 770,000	$ 121,000	$ 275,000	$ 255,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	Dec. 12, 2017	Jun. 08, 2017
Private Placement [Member]
Stockholders Equity Note [Line Items]
Stock Issued During Period, Shares, New Issues		1,900
Proceeds from Issuance of Private Placement		$ 7.6
Equity Issuance Per Share Amounts		$ 4
Underwritten Public Offering [Member]
Stockholders Equity Note [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	2,350
Sale of Stock, Price Per Share	$ 8.50
Sale of Stock, Consideration Received on Transaction	$ 21.2
Over-Allotment Option [Member]
Stockholders Equity Note [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	135,670

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Proceeds from Short Swing Profit Judgment Offset with Settlement Expense	$ 18	$ 0
Share Holder [Member]
Proceeds from Short Swing Profit Judgment Offset with Settlement Expense	18
Gross Proceeds from Short Swing Profit Judgment Offset with Settlement Expense	25
Payments for Legal Legal Fees and Taxes	$ 7

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Thousands	Dec. 31, 2018USD ($)
Rostislav Raykov [Member]
Severance Costs Payable In Case Of Termination Other Than For Cause	$ 350,000
Robert Andrade [Member]
Severance Costs Payable In Case Of Termination Other Than For Cause	$ 125,000

Subsequent events - Additional

Subsequent events - Additional Information (Details) - Loan and Security Agreement [Member] - Bridge Bank [Member] $ / shares in Units, shares in Thousands, $ in Millions	Feb. 01, 2019USD ($)$ / sharesshares
Debt Instrument, Interest Rate, Stated Percentage	1.00%
Subsequent Event [Member] | Term Loan [Member]
Line of Credit Facility, Maximum Borrowing Capacity | $	$ 12.5
Debt Instrument, Basis Spread on Variable Rate	5.50%
Debt Instrument, Interest Rate, Stated Percentage	1.00%
Shares, Issued | shares	39,130
Shares Issued, Price Per Share | $ / shares	$ 6.80

Income Taxes (Canadian federal

Income Taxes (Canadian federal and provincial income tax rate) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Schedule Of Effective Tax Rate [Line Items]
Domestic (loss)/gain	$ (7,702)	$ (5,277)
Foreign loss	(2,145)	(1,769)
Loss before income taxes	$ (9,847)	$ (7,046)
Expected statutory rate (recovery)	26.50%	26.50%
Expected provision for (recovery of) income tax	$ (2,609)	$ (1,867)
Permanent differences	512	636
Change in valuation allowance	2,042	328
Effect of foreign exchange rate differences	0	0
Effect of change in future enacted tax rates	0	843
Tax credits and other adjustments	0	(3)
Effect of tax rate changes and other	55	63
Provision for income taxes	$ 0	$ 0

Income Taxes (Future Income Tax

Income Taxes (Future Income Taxes (Recovery)) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	$ 26,020	$ 23,920
Less: valuation allowance	(26,020)	(23,920)
Net future tax assets	0	0
Income tax loss carryforwards [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	21,452	19,431
Fixed and intangible assets [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	1,065	1,031
Reserves [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	13	0
SR & ED expenditures [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	2,195	2,195
Non-refundable investment tax credits [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	1,250	1,263
Share issue costs [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	45	0
Accrued expenses [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	$ 0	$ 0

Income Taxes (Income Tax Loss C

Income Taxes (Income Tax Loss Carry Forwards And Non-Refundable Investment tax Credits) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Province State [Member]
Income Tax [Line Items]
SR & ED expenditures (no expiry)	$ 0
Province State [Member] | Year 2019 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,455
Province State [Member] | Year 2020 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	4,768
Province State [Member] | Year 2021 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	8,885
Province State [Member] | Year 2022 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	4,219
Province State [Member] | Year 2023 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	4,164
Province State [Member] | Year 2024 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	2,116
Province State [Member] | Year 2025 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	700
Province State [Member] | Year 2026 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	12,454
Province State [Member] | Year 2027 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	4,764
Province State [Member] | Year 2028 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	7,314
Province State [Member] | Year 2029 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	7,003
Province State [Member] | Year 2030 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	2,741
Province State [Member] | Year 2031 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	3,448
Province State [Member] | Year 2032 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	4,370
Province State [Member] | Year 2033 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	3,156
Province State [Member] | Year 2034 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,606
Province State [Member] | Year 2035 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	861
Province State [Member] | Year 2036 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,189
Province State [Member] | Year 2037 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	2,882
Province State [Member] | Year 2038 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	5,655
Province State [Member] | No expiration [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	0
Federal [Member]
Income Tax [Line Items]
SR & ED expenditures (no expiry)	8,283
Federal [Member] | Year 2019 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	0
Investment tax credits (expiry date)	96
Federal [Member] | Year 2020 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	0
Investment tax credits (expiry date)	55
Federal [Member] | Year 2021 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	26
Investment tax credits (expiry date)	548
Federal [Member] | Year 2022 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	233
Investment tax credits (expiry date)	399
Federal [Member] | Year 2023 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	133
Investment tax credits (expiry date)	178
Federal [Member] | Year 2024 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,536
Investment tax credits (expiry date)	199
Federal [Member] | Year 2025 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	4,795
Investment tax credits (expiry date)	86
Federal [Member] | Year 2026 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	20,562
Investment tax credits (expiry date)	90
Federal [Member] | Year 2027 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	8,340
Investment tax credits (expiry date)	50
Federal [Member] | Year 2028 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	10,840
Federal [Member] | Year 2029 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	8,502
Federal [Member] | Year 2030 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	2,608
Federal [Member] | Year 2031 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	3,378
Federal [Member] | Year 2032 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	3,491
Federal [Member] | Year 2033 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,789
Federal [Member] | Year 2034 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,812
Federal [Member] | Year 2035 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,804
Federal [Member] | Year 2036 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	2,208
Federal [Member] | Year 2037 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	4,641
Federal [Member] | Year 2038 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	5,655
Federal [Member] | No expiration [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	$ 2,160

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Taxes Disclosure Additional Information [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	26.50%	26.50%
Canadian Statutory Income Tax [Member]
Income Taxes Disclosure Additional Information [Line Items]
Income tax Rate	26.00%
Federal Income Tax [Member]
Income Taxes Disclosure Additional Information [Line Items]
Income tax Rate	15.00%
Provincial Income Tax [Member]
Income Taxes Disclosure Additional Information [Line Items]
Income tax Rate	11.00%
Scenario, Plan [Member]
Income Taxes Disclosure Additional Information [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%